coin-img-ETHETH+2.28%coin-img-BTCBTC+0.92%coin-img-SOLSOL+0.32%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.80%coin-img-TRXTRX-0.24%coin-img-BNBBNB+1.02%coin-img-HYPEHYPE+3.59%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.92%coin-img-SOLSOL+0.32%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.80%coin-img-TRXTRX-0.24%coin-img-BNBBNB+1.02%coin-img-HYPEHYPE+3.59%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.92%coin-img-SOLSOL+0.32%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.80%coin-img-TRXTRX-0.24%coin-img-BNBBNB+1.02%coin-img-HYPEHYPE+3.59%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.92%coin-img-SOLSOL+0.32%coin-img-USDCUSDC+0.00%coin-img-XRPXRP-0.80%coin-img-TRXTRX-0.24%coin-img-BNBBNB+1.02%coin-img-HYPEHYPE+3.59%
user-avatar
Benzinga

Eli Lilly shares rise after Q2 revenue jumps 48% to $22.97 billion and adjusted EPS tops estimates

AI Market Summary
Eli Lilly's Q2 results beat expectations, led by strong GLP-1 demand: Mounjaro and Zepbound generated $14.9B and added $6.3B YoY. Revenue rose 48% to $22.97B and adjusted EPS reached $8.38, both above consensus. Management highlighted expanding manufacturing capacity, pipeline progress, and raised FY2026 revenue guidance, reinforcing confidence in sustained growth despite lower realized prices.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT+4.95%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly reported second-quarter revenue of $22.97 billion, up 48% year over year and above the $20.73 billion consensus estimate, while adjusted earnings were $8.38 per share versus $6.01 expected. Sales of its diabetes and weight-loss drugs Mounjaro and Zepbound totaled $14.9 billion, up $6.3 billion from a year earlier, reflecting sustained demand. The company is expanding manufacturing capacity and its product lineup to reinforce its lead in the GLP-1 market. The results helped lift the stock.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.